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ABSTRACT
Nadroparin, a low molecular weight heparin, has prophylactic and therapeutic use in thromboembolic disorder. In a patient with carcinoma ovary 
stage 3 B, nadroparin was given prophylactically for deep vein thrombosis (DVT) before and after interval cytoreduction surgery. Nadroparin 0.3 ml 
was given subcutaneously once daily for 1 day preoperatively and 8 days postoperatively. Rise in serum potassium was observed on the third post-
operative day suggestive of hyperkalemia. Intravenous fluids were given, and the drug was stopped on the 9th post-operative day and hyperkalemia 
resolved after 2 days. Monitoring of serum potassium level is essential when Nadroparin is administered prophylactically for more than 7 days for 
DVT. As this case illustrates a causal relationship between nadroparin and hyperkalemia, caution must be exercised with nadroparin.
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INTRODUCTION
Heparin, an anticoagulant, is used in prophylaxis and treatment of 
deep vein thrombosis (DVT), pulmonary thromboembolism, and 
post-myocardial infarction. It is now being replaced by low molecular 
weight heparin (LMWH) in view of better bioavailability, efficacy, 
less frequent dosing, and no requirement of a partial thromboplastin 
time monitoring. Known side effects of heparin are osteoporosis, 
skin necrosis, hypersensitivity reactions, thrombocytopenia, and 
hemorrhage. LMWH has lesser side effects giving it an advantage over 
heparin [1]. Hyperkalemia is a common clinical condition defined as 
serum potassium concentration exceeding 5 mmol/L.
We report a case of hyperkalemia induced by nadroparin used for post-
surgical DVT prophylaxis in a patient with advanced carcinoma ovary.
CASE REPORT
A 49-year-old female (informed consent obtained) a known case of 
carcinoma ovary was planned for cytoreduction interval surgery after 
3 cycles of neoadjuvant chemotherapy with paclitaxel. As a measure of 
DVT prophylaxis patient was started on LMWH 0.3 ml subcutaneous 
once daily 24 hrs before surgery. Pre-operative evaluation was normal, 
and serum electrolyte levels were within normal limit. 3 days after 
receiving nadroparin there was an alteration in the serum potassium 
level with a significant rise above the baseline with K+ values rising 
from 3.8 to 5.6 mmol/L. Here, the baseline K+ value is considered to 
be 3.5-5 mmol/L. Nadroparin was continued until 8th post-operative 
day. As a part of intervention intravenous fluid correction was given 
and nadroparin on was stopped on 9th post-operative day and serum 
K+ values returned to normal to baseline after 2 days of stopping 
nadroparin (Table 1).
Review of the case revealed that patient was not on any other medication 
other than nadroparin that could predispose to hyperkalemia. Renal 
insufficiency or diabetes that could cause hyperkalemia was excluded. 
The patient was asymptomatic with normal electrocardiogram and 
vitals.
DISCUSSION
Drug-induced hyperkalemia is one of the most common causes of 
hyperkalemia in hospital setting in everyday practice. A wide range 
of drugs can cause hyperkalemia by a variety of mechanisms like 
promotion of transcellular shift of K+, by impairing K+ excretion or 
increasing K+ supply. A high risk of hyperkalemia is seen in those 
having hypoaldosteronism, chronic renal insufficiency, and taking 
medications that can increase K+ levels. Recognition of medications that 
impair potassium homeostasis is essential for proper clinical care and 
management [2].
Unfractioned and LMWH are used in the management of medical and 
surgical diseases. Hyperkalemia, a rare but recognized side effect 
with lower incidence due to LMWH in comparison to incidence of 7% 
with heparin is usually overlooked in clinical practice [3]. However, 
there are no conclusive reports on LMWH induced hyperkalemia 
and its incidence cannot be actually defined. The mechanisms by 
which heparin produces hyperkalemia is still debatable but various 
mechanisms put forth are inhibition of enzyme involved in synthesis 
of aldosterone, namely 18-alpha hydroxylase, reduction in number 
as well as affinity of angiotensin II receptors in zona glomerulosa. 
Heparin causes marked reduction in width of adrenal zona glomerulosa 
thereby leading to aldosterone suppression. Aldosterone suppression 
results in natriuresis and decreased excretion of potassium leading to 
hyperkalemia [4-6].
A risk of heparin-induced hyperkalemia is higher in patients with 
preexisting diabetes mellitus, renal failure, patients on potassium 
sparing drugs where K+ levels should be measured before and after 
initiating heparin treatment [4-6]. Clinical studies [3,4,7-9] have 
been published on this issue, the latest being the work of Torres et al. 
reflecting the continued clinical implication of this rare but relevant 
complication [7]. Potassium monitoring is important in the case of 
treatment with heparin for more than 7 days. However, hyperkalemia 
can still occur within a span of 3 days as in this case. Causality 
assessment as per, Naranjo’s scale [10] indicates the adverse effect to 
be probable due to nadroparin.
CONCLUSION
This case illustrates the need of cautious administration and monitoring 
of serum potassium levels in post-surgical DVT prophylaxis patients 
receiving nadroparin for more than a week. Monitoring of levels on the 
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4th day after initiation of nadroparin is recommended. Now that LMWH 
is preferred over heparin, so it becomes imperative to monitor K+ levels 
regularly.
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